Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA grants Galenica/Luitpold OK to market anemia drug Injectafer

This article was originally published in Scrip

Executive Summary

Shares of Galenica jumped more than 8% on the Six Swiss Exchange on 26 July after the company and its partner Luitpold Pharmaceuticals gained approval from the FDA to market Injectafer (ferric carboxymaltose) as a treatment for iron deficiency anemia (IDA) in US adults who have had an unsatisfactory response to oral iron or who have intolerance to oral iron.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts